Ascendis Pharma A/S

Ascendis Pharma A/S (ASND) is currently trading at $230.83, with a 52-week range of $160.86 to $250.74. Reaching the $277 level would represent a 20% gain from the current price — a target many investors consider when evaluating near-term upside potential.

Wall Street analysts currently have a consensus price target of $292.09 for Ascendis Pharma A/S, with a Strong_buy rating, and the most bullish analysts see the stock reaching as high as $348.67. Whether Ascendis Pharma A/S can reach $277 in 2026 depends on several factors: revenue and earnings growth trajectory, broader market conditions, sector sentiment within the Healthcare space, and any company-specific catalysts such as product launches, earnings beats, or strategic announcements.

Short-term price predictions carry significant uncertainty — stock prices can be influenced by factors ranging from quarterly earnings surprises to global macroeconomic events. Use the ASND Stock Return Calculator on StockSifting to model different growth scenarios and see how various CAGR assumptions translate to potential price targets. This content is for informational purposes only and does not constitute financial advice.

Whether Ascendis Pharma A/S (ASND) is worth buying at $230.83 depends on your investment goals, time horizon, and risk tolerance. Here is a breakdown of the key metrics investors typically evaluate:

Valuation: Ascendis Pharma A/S trades at a Price-to-Earnings (P/E) ratio of 26.3x, which can be compared against other Healthcare companies to assess whether the stock is expensive or attractively priced relative to its peers.

Profitability & efficiency: Its Return on Equity (ROE) stands at 3.3%.

Financial health: The Debt-to-Equity ratio of 183.75 indicates a higher degree of financial leverage — investors should monitor debt servicing capacity.

Analyst view: The Wall Street consensus recommendation for ASND is currently Strong_buy, with a mean price target of $292.09 based on 18 analyst ratings. Always conduct your own due diligence and consider consulting a qualified financial advisor before making any investment decisions. Nothing on StockSifting constitutes financial advice.

As of 2026, Wall Street analysts have set a consensus (mean) price target of $292.09 for Ascendis Pharma A/S (ASND), aggregated from 18 analyst ratings. The overall analyst recommendation is Strong_buy.

The price target range spans from $248.63 on the bearish end to $348.67 on the most optimistic projection, with a median target of $288.59. This wide range reflects differing views on Ascendis Pharma A/S's growth prospects, competitive positioning, and macroeconomic sensitivity.

It is important to note that analyst price targets are forward-looking estimates based on financial models, earnings projections, and sector assumptions — they are not guarantees. Targets are regularly revised following quarterly earnings results, management guidance updates, or shifts in the broader economic outlook. Stocks can trade significantly above or below analyst targets depending on market conditions. View the full analyst breakdown and track target revisions on the ASND analysis page on StockSifting.

Ascendis Pharma A/S (ASND) currently has a Price-to-Earnings (P/E) ratio of 26.3x, meaning investors are paying $26.3 for every $1 of the company's trailing twelve-month earnings. Whether this makes the stock overvalued depends on several contextual factors:

Sector context: The Healthcare sector tends to command higher valuation multiples when growth expectations are elevated. A 26.3x P/E falls within a moderate range, reflecting reasonable market confidence in Ascendis Pharma A/S's earnings outlook.

Growth-adjusted valuation: A P/E ratio in isolation can be misleading. Fast-growing companies often deserve higher P/E multiples because their future earnings are expected to rise significantly. A more complete picture comes from looking at the PEG ratio (P/E divided by earnings growth rate) — a PEG below 1 is often considered undervalued, while above 2 may signal overvaluation.

Additional metrics to review: P/E is just one lens. Compare it alongside the Price-to-Book (P/B) ratio, EV/EBITDA, Price-to-Sales, and free cash flow yield for a more complete valuation picture. View all of ASND's valuation ratios on StockSifting's ratios section. Valuation is subjective and context-dependent — this is not investment advice.

Projecting Ascendis Pharma A/S (ASND)'s stock price 3 years into the future — to 2029 — requires making assumptions about the company's earnings growth, valuation multiple, and broader market conditions. No projection is guaranteed, but historical growth rates offer a reasonable starting point.

In reality, stock prices rarely follow a straight-line trajectory. Short-term volatility, earnings misses, sector rotations, interest rate changes, and macroeconomic events can all cause significant deviations from any modeled path. Investors with a 3-year horizon should focus on the fundamental business trajectory — revenue growth, expanding margins, and free cash flow generation — rather than short-term price fluctuations.

You can model different scenarios — conservative, base, and bull case — using the ASND Return Calculator on StockSifting. Enter any investment amount and CAGR assumption to see projected outcomes over your chosen time horizon. All projections are mathematical estimates only and do not constitute financial advice.